Valuation: Assembly Biosciences, Inc.

Market Cap 483M 420M 391M 359M 678M 46.14B 689M 4.61B 1.81B 22.97B 1.82B 1.78B 77.03B P/E 2026 *
-23.2x
P/E 2027 * -8.76x
Enterprise Value 483M 420M 391M 359M 678M 46.14B 689M 4.61B 1.81B 22.97B 1.82B 1.78B 77.03B EV / Sales 2026 *
10.6x
EV / Sales 2027 * 15x
Free-Float
71.58%
Yield 2026 *
-
Yield 2027 * -
1 day-3.65%
1 week-1.72%
1 month-8.62%
3 months-6.83%
6 months-2.58%
Current year-26.17%
1 week 24.5
Extreme 24.5
26.56
1 month 24.5
Extreme 24.5
29.94
Current year 21.8
Extreme 21.795
34.68
1 year 17.98
Extreme 17.98
39.7
3 years 7.69
Extreme 7.692
39.7
5 years 7.69
Extreme 7.692
47.28
10 years 7.69
Extreme 7.692
808.32
Manager TitleAgeSince
Chief Executive Officer 50 2022-12-31
Director of Finance/CFO - 2025-06-04
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 70 2026-06-03
Director/Board Member 61 2017-12-13
Director/Board Member 68 2019-08-05
Date Insider Type Main position Quantity % Market Cap.
6/4/26 Free

Director

8,000 0.0514%
3/29/26 Free

Chief Technology Officer

26,000 0.1671%
8/8/25 BuyCompany 4,591,840 72.2409%
Change 5-day change 1-year change 3-year change Capi.($)
-3.65%-1.72%+40.08%+88.51% 502M
-1.40%+2.59%-1.71%+11.28% 49.37B
-2.41%-0.90%+403.17%+614.40% 40.85B
-1.16%+12.96%+26.45%+5.03% 39.14B
-1.88%-3.03%+4.94%+47.52% 35.81B
-1.74%+8.42%+8.85%+48.87% 30.5B
-2.85%-3.92% - - 16.55B
-0.21%-4.04%+35.09%+127.95% 16.14B
-0.64%+2.65%+1.25%+8.92% 13.71B
-1.19%-1.32%-3.32%-34.94% 12.77B
Average -1.71%+1.41%+57.20%+101.95% 25.54B
Weighted average by Cap. -1.60%+3.17%+77.18%+129.11%

Financials

2026 *2027 *
Net sales 45.47M 39.53M 36.79M 33.78M 63.79M 4.34B 64.78M 434M 170M 2.16B 171M 167M 7.25B 32.25M 28.03M 26.09M 23.96M 45.24M 3.08B 45.94M 308M 121M 1.53B 121M 118M 5.14B
Net income -20.46M -17.79M -16.56M -15.2M -28.71M -1.95B -29.15M -195M -76.6M -972M -76.85M -75.16M -3.26B -56.38M -49.01M -45.62M -41.88M -79.09M -5.38B -80.32M -538M -211M -2.68B -212M -207M -8.98B
Net Debt - -
Logo Assembly Biosciences, Inc.
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
Employees
73
Date Price Change Volume
26-07-31 US$25.11 -3.65% 101,353
26-07-30 US$26.06 +3.78% 55,726
26-07-29 US$25.11 -1.80% 153,276
26-07-28 US$25.57 -1.31% 86,407
26-07-27 US$25.91 +1.41% 79,179
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
25.11USD
Average target price
50.00USD
Spread / Average Target
+99.12%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ASMB Stock